EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-resolution metabolomic analysis of stool reveals expanded biomarkers of C. difficile colitis and insights into pathophysiology

Nirja Mehta iD, Vincent Guzzetta, Ken H Liu iD, Andrew S Webster, Max W Adelman iD, Eric C Fitts, Dean P Jones, Colleen S Kraft iD, Michael H Woodworth iD, Jeffrey M Collins iD

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.02826-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Nirja Mehta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Feces, Clostridioides difficile, Clostridium Infections, Metabolomics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridioides difficile infection (CDI) is facilitated by gut microbiome disruption and associated metabolic disturbances. While many prior studies have focused on the microbial composition of CDI stool, fewer have explored the fecal metabolome using untargeted high-resolution metabolomics (HRM). To characterize the metabolic phenotype of CDI, we performed untargeted HRM on stool samples from 55 CDI patients and 72 healthy controls. CDI was associated with marked alterations in stool metabolites, mapping to 14 significantly dysregulated pathways, including tryptophan metabolism, bile acid metabolism, short-chain fatty acid metabolism, and fatty acid oxidation. These findings suggest that CDI is associated with a distinct fecal metabolic milieu that may promote inflammation, impair colonization resistance, and facilitate C. difficile replication. Our results corroborate previous studies and support further investigation of the role of microbial and immune signaling in CDI as well as metabolic biomarkers and therapeutic targets. IMPORTANCE As we learn more about the essential role of gut microbes in human health and disease, there is an effort to identify and characterize stool biomarkers that distinguish patients with microbiome-associated disease from healthy individuals. Clostridioides difficile infection contributes to excess healthcare burden and is tightly linked to disruption of the gut microbiome (usually by use of antimicrobials). We compared the metabolome of healthy stool and C. difficile -infected stool to identify metabolites that correlate with disease and may support the development of improved diagnostic tests for C. difficile infection. In comparing these two groups, we found chemical pathways that strongly correlate with disease and others more associated with healthy stool, including bile acid biosynthesis, tryptophan metabolism, and carnitine activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FecesClostridioides difficileClostridium InfectionsMetabolomicsColitisHumansBiomarkersMetabolomeFemaleGastrointestinal MicrobiomeMaleBile Acids and SaltsMiddle AgedAgedAdult

Stichwörter der Autor:innen

C. difficileClostridioidesdiagnostic testingmetabolomics

Substanzen

BiomarkersBile Acids and Salts

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
  • Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, Houston Methodist Hospital, Houston, Texas, USA.

ORCID-Profile: Nirja Mehta, Ken H Liu, Max W Adelman, Colleen S Kraft, Michael H Woodworth, Jeffrey M Collins

Förderung

  • NIAID NIH HHS

Zitieren

APA

Mehta, N., Guzzetta, V., Liu, K. H., Webster, A. S., Adelman, M. W., Fitts, E. C., Jones, D. P., Kraft, C. S., Woodworth, M. H., & Collins, J. M. (2026). High-resolution metabolomic analysis of stool reveals expanded biomarkers of C. difficile colitis and insights into pathophysiology. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02826-25

Vancouver

Mehta N, Guzzetta V, Liu KH, Webster AS, Adelman MW, Fitts EC, et al. High-resolution metabolomic analysis of stool reveals expanded biomarkers of C. difficile colitis and insights into pathophysiology. Microbiology Spectrum. 2026. doi:10.1128/spectrum.02826-25

BibTeX
@article{Mehta2026,
  author = {Mehta, Nirja and Guzzetta, Vincent and Liu, Ken H and Webster, Andrew S and Adelman, Max W and Fitts, Eric C and Jones, Dean P and Kraft, Colleen S and Woodworth, Michael H and Collins, Jeffrey M},
  title = {High-resolution metabolomic analysis of stool reveals expanded biomarkers of C. difficile colitis and insights into pathophysiology},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.02826-25}
}
Kostenlos starten →